This content is intended for healthcare professionals in Europe only.

Please confirm that you are a healthcare professional in Europe.

to access this content

This activity has been sponsored by Advanced Accelerator Applications International SA. Advanced Accelerator Applications International SA provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY / touchENDOCRINOLOGY.

This content is intended for healthcare professionals in Europe only.

Please confirm that you are a healthcare professional in Europe.

Decline

This activity has been sponsored by Advanced Accelerator Applications International SA. Advanced Accelerator Applications International SA provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY / touchENDOCRINOLOGY.

touchFEATURE

Efficacy and safety results from the Phase 3 NETTER-1 trial with LUTATHERA® (lutetium (177Lu) oxodotreotide)

Access to this content is not permitted for healthcare professionals based in the US.

Back to Learning Zone

Prescribing Infomation

Gastrointestinal Oncology, Neuroendocrine Tumours, Pancreatic Cancer View Time: 20 mins

touchFEATURE Efficacy and safety results from the Phase 3 NETTER-1 trial with LUTATHERA® (lutetium (177Lu) oxodotreotide)

Discover key efficacy and safety results from an international Phase 3 clinical trial of LUTATHERA® in patients with midgut neuroendocrine tumours (NET).1

 
Videos
LUTATHERA®: Radioligand therapy for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET)

Dr Isabel Sevilla, Virgen de la Victoria University Hospital, Málaga, Spain, explains the rationale for targeted radioligand therapy in GEP-NET and specific mechanism of action of LUTATHERA®.5

1/5 Next Chapter
 
Progression-free survival: primary analysis of the Phase 3 NETTER-1 clinical trial

Progression-free survival was the primary endpoint of the NETTER-1 study.1 Dr Alejandro García, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the significant reduction of risk of disease progression or death observed with LUTATHERA® plus octreotide LAR 30mg vs. active control (octreotide LAR 60mg*).1

2/5 Next Chapter
 
Overall survival with LUTATHERA®: final analysis from the NETTER-1 clinical trial

Overall survival (OS) was a key secondary endpoint in the Phase 3 NETTER-1 clinical trial of LUTATHERA® plus octreotide LAR 30mg vs active control (octreotide LAR 60mg*).4 Dr Enrique Grande, MD Anderson Cancer Center, Madrid, Spain, reviews the final OS analysis, conducted after a median follow-up of more than 6 years in the NETTER-1 study.4

*High-dose octreotide LAR 60mg is not the licensed dose.

3/5 Next Chapter
 
Health-related quality of life with LUTATHERA®

Dr Henning Jann, Charité University Hospital, Berlin, Germany, describes results from NETTER-1 which demonstrated statistically significant and clinically robust quality of life benefits for patients with inoperable, progressive midgut NET receiving LUTATHERA® plus octreotide LAR 30mg vs. active control (octreotide LAR 60mg*).2

*High-dose octreotide LAR 60mg is not the licensed dose.

4/5 Next Chapter
 
Long-term safety profile of LUTATHERA®

Dr Nicola Fazio, European Institute of Oncology, Milan, Italy, discusses the overall safety profile of LUTATHERA®, based on pooled data from clinical studies (NETTER-1 pivotal Phase 3 clinical trial and Erasmus Phase1/2 clinical trial in Dutch patients) and from compassionate use programs.5

5/5 Leave Feedback
Leave Feedback
Overview & Learning Objectives
Overview

NETTER-1 is an international Phase 3 clinical trial comparing LUTATHERA® plus best supportive care (30mg octreotide long-acting repeatable [LAR]) vs. high-dose octreotide LAR 60mg*) for patients with inoperable, progressive, somatostatin receptor (SSTR)-positive midgut neuroendocrine tumours (NET).1 Results demonstrate significantly improved progression-free survival, quality of life benefits and symptom reduction in the LUTATHERA® arm vs. high-dose octreotide LAR 60mg.1-3

*High-dose octreotide LAR 60mg is not the licensed dose.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the mechanism of action of LUTATHERA®4,5
  • Recall the objectives and design of the NETTER-1 study1
  • Describe the efficacy of LUTATHERA® in patients with midgut NET1-4
  • Discuss symptom control and quality of life outcomes from NETTER-12,3
  • Describe the long-term safety profile of LUTATHERA®4,5
Adverse Events
Adverse Events

Adverse events should be reported by accessing this link: https://www.adacap.com/pharmacovigilance/

References
References
  1. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135.
  2. Strosberg J, Wolin E, Chasen B, et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018;36(25):2578-2584.
  3. Strosberg JR, Srirajaskanthan R, El-Haddad G, et al. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE. J Nucl Med. 2021;62(12):1712-1718.
  4. Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial [published correction appears in Lancet Oncol. 2022 Feb;23(2):e59]. Lancet Oncol. 2021;22(12):1752-1763.
  5. LUTATHERA Summary of Product Characteristics. 14 July 2022. Available at: www.ema.europa.eu/documents/product-information/lutathera-epar-product-information_en.pdf (accessed July 2022).
Downloads

View and download resources from this activity to support your learning and share with colleagues

Feedback Close
Feedback

Please provide feedback for this touchFEATURE on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72